The fractional flow reserve (FFR) approach is no better than angiography-guided strategy in patients with multivessel STEMI* undergoing complete revascularization in the head-to-head FLOWER-MI trial**.
Left atrial appendage occlusion (LAAO) added to usual care led to a reduction in ischaemic stroke or non-cerebral systemic embolism following cardiac surgery among patients with atrial fibrillation (AF), according to results of the LAAOS* III trial.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.
Treatment with finerenone led to a significantly reduced risk of new-onset atrial fibrillation (AF) in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), according to the FIDELIO-DKD* trial presented at the ACC.21 Virtual Meeting.
Long-term maintenance monotherapy with clopidogrel is superior to aspirin in reducing the risk of both ischaemic and major bleeding events in patients who had successfully undergone 6–18 months of DAPT* without any clinical event following a percutaneous coronary intervention (PCI), the head-to-head HOST-EXAM** trial has shown.
The oral antifibrotic agent pirfenidone – a drug currently approved for the treatment of idiopathic lung fibrosis – significantly reduced scarring of the heart muscle in individuals with chronic heart failure with preserved ejection fraction (HFpEF) and myocardial fibrosis, according to findings from the early-phase PIROUETTE trial presented at ACC.21.
Ultrasound renal denervation (RDN) offers a blood-pressure (BP) lowering benefit for individuals with triple drug-resistant hypertension compared with a sham procedure, according to the RADIANCE-HTN TRIO trial presented at ACC.21.
The sodium glucose cotransporter 1/2 inhibitor sotagliflozin reduced the primary composite endpoint of cardiovascular (CV) deaths, hospitalizations for heart failure (HF), and urgent visits for HF in patients with type 2 diabetes and HF, including those with HF with preserved ejection fraction (HFpEF; EF ≥50 percent), according to the pooled analysis of the SOLOIST* and SCORED** trials presented at ACC.21.